This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chun, J. H. Articles by Park, J.-G. Search for Related Content PubMed PubMed Citation Articles by Chun, J. H. Articles by Park, J.-G.

Increased Expression of Metallothionein Is Associated with Irinotecan Resistance in Gastric Cancer

¹ Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi; ² Seoul National University Biomedical Informatics, Department of Preventive Medicine, Seoul National University College of Medicine, Seoul; and ³ Korean Hereditary Tumor Registry, Laboratory of Cell Biology, Cancer Research Center and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea

To gain insight into clinically relevant mechanisms of irinotecan resistance, we undertook oligonucleotide microarray analyses on paired malignant effusion samples obtained from eight gastric cancer patients treated with weekly irinotecan. Pretreatment and posttreatment (48 h) effusion samples were obtained for each patient, and the change in expression profile was compared between clinical responders and nonresponders. When differences in the expression of genes were examined using SAM (Significance Analysis of Microarrays) software, five isoforms of the metallothionein family were identified to have significantly higher signal log ratios in five nonresponders, compared with three responders. Compared with control cells, metallothionein 1X (MT1X)-transfected AGS cells showed a 1.4-fold higher irinotecan IC₅₀ by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and tended to form more colonies. These findings collectively suggest that irinotecan-induced up-regulation of metallothionein might be associated with irinotecan resistance in patients with gastric cancer, although it remains to be confirmed in a larger data set.

This article has been cited by other articles:

				W. L. Allen, V. M. Coyle, P. V. Jithesh, I. Proutski, L. Stevenson, C. Fenning, D. B. Longley, R. H. Wilson, M. Gordon, H.-J. Lenz, et al. Clinical Determinants of Response to Irinotecan-Based Therapy Derived from Cell Line Models Clin. Cancer Res., October 15, 2008; 14(20): 6647 - 6655. [Abstract] [Full Text] [PDF]

				Y. Huang, H. Li, H. Hu, X. Yan, M. S. Waterman, H. Huang, and X. J. Zhou Systematic discovery of functional modules and context-specific functional annotation of human genome Bioinformatics, July 1, 2007; 23(13): i222 - i229. [Abstract] [Full Text] [PDF]

				H. Was, T. Cichon, R. Smolarczyk, D. Rudnicka, M. Stopa, C. Chevalier, J. J. Leger, B. Lackowska, A. Grochot, K. Bojkowska, et al. Overexpression of Heme Oxygenase-1 in Murine Melanoma: Increased Proliferation and Viability of Tumor Cells, Decreased Survival of Mice Am. J. Pathol., December 1, 2006; 169(6): 2181 - 2198. [Abstract] [Full Text] [PDF]

				J. K. Choi, U. Yu, O. J. Yoo, and S. Kim Differential coexpression analysis using microarray data and its application to human cancer Bioinformatics, December 15, 2005; 21(24): 4348 - 4355. [Abstract] [Full Text] [PDF]